Crossmark

Systemic delivery of a specific antibody targeting the pathological N-terminal truncated tau peptide reduces retinal degeneration in a mouse model of Alzheimer’s Disease

Crossref DOI link: https://doi.org/10.1186/s40478-021-01138-1

Published Online: 2021-03-09

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Latina, Valentina

Giacovazzo, Giacomo

Cordella, Federica

Balzamino, Bijorn Omar

Micera, Alessandra

Varano, Monica

Marchetti, Cristina

Malerba, Francesca

Florio, Rita

Ercole, Bruno Bruni

La Regina, Federico

Atlante, Anna

Coccurello, Roberto

Di Angelantonio, Silvia

Calissano, Pietro

Amadoro, Giuseppina http://orcid.org/0000-0003-2080-2951
License Information

Text and Data Mining valid from 2021-03-09

Version of Record valid from 2021-03-09
More Information

Article History

Received: 17 November 2020

Accepted: 26 February 2021

First Online: 9 March 2021

Declarations

:

: All animal experiments were complied with the ARRIVE guidelines and were carried out in accordance with the guidelines of the European Council Directive (2010/63/EU) and with the ethical standards of the Italian Ministry of Health (Authorization No. 524/2017 PR; Authorization No. 1038-2020-PR).

: All authors have seen and approved the manuscript.

: P.C. and G.A have intellectual property through CNR-EBRI regarding 12A12mAb.

Document is current

Any future updates will be listed below